Literature DB >> 27546969

Refractory asthma - An old disorder: Novel approaches for effective control.

B N B M Prasad1.   

Abstract

Bronchial asthma is an inflammatory disorder of airways characterized by hyper-responsiveness to a wide range of triggers and is associated with variable airflow obstruction that remits spontaneously or with the treatment. Several phenotype of asthma not responding to the currently acceptable standard therapy of high dose inhaled gluco-corticosteroids along with along acting β2 agonists come under the purview of refractory asthma. This condition is a heterogeneous and complex disease that requires a multi-disciplinary approach to identify accurately various sub-phenotypes to enable improved understanding of the pathogenesis and development of effective management strategies including use of novel methods and targeted therapy.

Entities:  

Keywords:  Phenotypes; Refractory asthma; Targeted therapy; Therapeutic options; Triggers

Year:  2016        PMID: 27546969      PMCID: PMC4982976          DOI: 10.1016/j.mjafi.2016.04.006

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  30 in total

1.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

Review 2.  Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Authors:  Gustavo J Rodrigo; Hugo Neffen; José A Castro-Rodriguez
Journal:  Chest       Date:  2010-08-05       Impact factor: 9.410

3.  Obesity and asthma: an association modified by age of asthma onset.

Authors:  Fernando Holguin; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Serpil C Erzurum; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; Wendy C Moore; Stephen P Peters; Michael Yonas; W Gerald Teague; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2011-06       Impact factor: 10.793

Review 4.  Allergic bronchopulmonary aspergillosis.

Authors:  Ritesh Agarwal
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

5.  Treatment of chronic rhinosinusitis and its effects on asthma.

Authors:  S Ragab; G K Scadding; V J Lund; H Saleh
Journal:  Eur Respir J       Date:  2006-03-01       Impact factor: 16.671

6.  "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids.

Authors:  Anneke ten Brinke; Aeilko H Zwinderman; Peter J Sterk; Klaus F Rabe; Elisabeth H Bel
Journal:  Am J Respir Crit Care Med       Date:  2004-06-23       Impact factor: 21.405

7.  Cluster analysis of obesity and asthma phenotypes.

Authors:  E Rand Sutherland; Elena Goleva; Tonya S King; Erik Lehman; Allen D Stevens; Leisa P Jackson; Amanda R Stream; John V Fahy; Donald Y M Leung
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

8.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

9.  Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.

Authors:  Jean Bousquet; Eva Mantzouranis; Alvaro A Cruz; Nadia Aït-Khaled; Carlos E Baena-Cagnani; Eugene R Bleecker; Chris E Brightling; Peter Burney; Andrew Bush; William W Busse; Thomas B Casale; Moira Chan-Yeung; Rongchang Chen; Badrul Chowdhury; Kian Fan Chung; Ronald Dahl; Jeffrey M Drazen; Leonardo M Fabbri; Stephen T Holgate; Francine Kauffmann; Tari Haahtela; Nikolaï Khaltaev; James P Kiley; Mohammad R Masjedi; Yousser Mohammad; Paul O'Byrne; Martyn R Partridge; Klaus F Rabe; Alkis Togias; Christiaan van Weel; Sally Wenzel; Nanshan Zhong; Torsten Zuberbier
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

10.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.

Authors:  Edward Piper; Christopher Brightling; Robert Niven; Chad Oh; Raffaella Faggioni; Kwai Poon; Dewei She; Chris Kell; Richard D May; Gregory P Geba; Nestor A Molfino
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.